HIH News

Promising immune response to cancer vaccine

Prof. Dr. Dr. Ghazaleh Tabatabai, Head of the Department of "Neurology and Interdisciplinary Neuro-Oncology", together with the Tübingen-based biopharmaceutical company CureVac, presented the first promising data from the dose escalation part A of the ongoing phase 1 study with the cancer vaccine CVGBM in patients with glioblastoma at the Congress of the European Society for Medical Oncology (ESMO) in Barcelona on September 13, 2024.

Read the press release from CureVac here

 

Picture: Prof. Dr. Dr. Ghazaleh Tabatabai